COVID-19 rebound not linked to Paxlovid, FDA says

The FDA reviewed Pfizer's mid-to-late stage clinical trials of Paxlovid and found "no evidence of a higher rate of symptom rebound or moderate symptom rebound."

Read the full post at Becker's Hospital Review - Healthcare News